Zai Lab Limited an innovation-driven, global biopharma company, shared the first data from a global Phase 1b clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with atezolizumab with and without carboplatin as...
Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by...
StimCardio Medical announced positive results from the randomized, double-blind, sham-controlled NeuroPulse pilot study evaluating non-invasive median nerve stimulation (MNS) following atrial fibrillation (AF) ablation. The study was selected for...
Acadia Pharmaceuticals Inc. announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and...
VERTANICAL announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component. The authorization marks a major milestone for VERTANICAL and highlights...
Nutraceutical ingredients innovator SUANNUTRA USA announces it has inked a distribution agreement with Spanish biotech company Fitoplancton Marino, S.L. to provide TetraSOD® for the North American market. TetraSOD® is a science-backed bioactive...
BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, announced the signing of a binding Heads of Terms agreement with Wellingto. Zhaotai Therapies Limited (Wellington Zhaotai) under which...
Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced positive results of an investigator-initiated...
Asahi Kasei Corporation has earned top honors in the 2025 BioTech Breakthrough Awards, winning the Biomanufacturing Innovation of the Year for its Planova™ FG1 virus removal filter, developed by its Asahi Kasei Bioprocess business unit. Designed...
Novartis announced that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment....
Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced new and updated results from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating IBTROZI™ (taletrectinib) for...
Theravance Biopharma, Inc. announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare and...
enGene Holdings Inc. a clinical-stage, non-viral gene-based immunotherapy company, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid (also...
Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZI™ (taletrectinib) for the treatment of adult...
Orthogon Therapeutics, a developer of novel antiviral medicines, announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its...
ImmunityBio, Inc. an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with...